Cobalt chloride inhibits tumor formation in osteosarcoma cells through upregulation of HIF-1α

BO ZHANG, WEICHUN GUO, LING YU, FU’AN WANG, YONG XU, YANG LIU and CHENGXIAO HUANG

Department of Orthopedics, Renmin Hospital, Wuhan University, Wuhan 430060, P.R. China

Received August 31, 2012; Accepted November 21, 2012

DOI: 10.3892/ol.2013.1127

Abstract. The exact effect of hypoxia on cancer development is controversial. The present study investigates the ability of osteosarcoma to form tumors in the hypoxic microenvironment induced by CoCl₂. MG63 human osteosarcoma cells were cultured with different concentrations (0, 150 and 300 µM) of CoCl₂ for 24 h to simulate hypoxia in vitro. The expression of hypoxia-inducible factor (HIF)-1α was analyzed by western blotting. The proliferation and drug resistance of MG63 cells were examined using the CCK-8 assay, the apoptosis rate was assessed by a spheroid culture system and invasiveness was determined by a vertical invasion assay. A transplantation assay was used to evaluate the ability to form tumors in vivo. Our results showed that the proliferation of MG63 cells was inhibited by treatment with CoCl₂, while no effect on drug toxicity was observed. The apoptotic rate was increased in a dose-dependent manner, the ability to form spheroids was suppressed, the invasiveness was inhibited and the expression of HIF-1α was upregulated following CoCl₂ treatment. We also found that the ability to form tumors in vivo was inhibited. In conclusion, we provide strong evidence that CoCl₂ has the ability to inhibit osteosarcoma development; the mechanism may be related to the hypoxic microenvironment and HIF-1α may be a critical regulatory factor.

Introduction

Osteosarcomas are primary malignant tumors of the bone which are now believed to be derived from malignant mesenchymal stem cells (MSCs) (1). The tumors mostly occur in the metaphyses of long bones, especially the distal femur, the proximal tibia and the proximal humerus (2). The World Health Organization (WHO) classifies conventional osteosarcoma into three main subtypes: osteoblastic, chondroblastic and fibroblastic (3). In the last 40 years, the application of adjuvant chemotherapy has improved the survival of osteosarcoma patients. However, the 5-year survival rate is only ~65% and the rates after recurrence or metastasis are worse, only ~30% (4). Without formal treatment, osteosarcoma migrates to other tissues, most commonly to the lung, in 6 months to one year and leads to mortality (5). Therefore, the effective treatment of osteosarcomas is worthy of study.

The tumor microenvironment is different from the normal environment of the body in physical and chemical properties, including hypoxia and low pH (6). In 1955, Thomlinson first noted that a number of malignant tumor tissues have hypoxic areas (7). Hypoxia-inducible factor-1 (HIF-1) was then identified by Semenza when he studied the expression of the erythropoietin gene induced by hypoxia (8). HIF-1 is a heterodimeric transcription factor composed of two subunits, oxygen-dependent HIF-1α and constitutively expressed HIF-1β (9). HIF-1α has been reported to activate the transcription of a set of genes which contribute to tumor aggressiveness, including VEGF, ENO1, TGF-α and CXCR4. By contrast, HIF-1α is also thought to inhibit tumor growth; for example, Carmeliet et al observed that tumors derived from HIF-1α-deficient embryonic stem (ES) cells formed larger tumors compared with wild-type (HIF-1α+/+) (10).

To investigate the effect of the hypoxic microenvironment on osteosarcoma, we used CoCl₂ to simulate a hypoxic microenvironment (11). There were two reasons why we selected CoCl₂ as the hypoxia-inducing agent. Firstly, Co²⁺ replaces Fe²⁺ in hemoglobin, forming deoxygenated hemoglobin. Secondly, Co²⁺ inhibits HIF-1α aryl hydrocarbon-hydroxylase activity to reduce HIF-1α degradation (12). Therefore, the features of CoCl₂-simulated hypoxia are similar to those of the in vivo hypoxic microenvironment. We treated a human osteosarcoma cancer cell line (MG63) with CoCl₂ to simulate hypoxia in vitro. Under the hypoxic conditions, we observed the characteristics of the cells, including proliferation, drug resistance, apoptosis and tumor formation, by CCK-8, flow cytometry (FCM) and spherocore system assays, respectively. Our results revealed that CoCl₂ stimulated a hypoxic microenvironment in vitro and inhibited tumor development.

Materials and methods

Reagents. The chemicals used were as follows: Fetal bovine serum (Gibco, USA); RPMI-1640 medium (Gibco); 2-(4-indophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2 H-tetrazolium

Correspondence to: Professor Weichun Guo, Department of Orthopedics, Renmin Hospital, Wuhan University, #238 Jiefang Road, Wuhan 430060, P.R. China
E-mail: guoweichun@yahoo.com.cn

Key words: hypoxia, CoCl₂, osteosarcoma, HIF-1α
monosodium salt (CCK-8; Santa Cruz Biotechnology, Santa Cruz, CA, USA); Annexin V-FITC/PI apoptosis detection kit (Santa Cruz Biotechnology); transwell chamber (Corning, USA); ultralow attachment plates (Corning); HIF-1α monoclonal antibody (Santa Cruz Biotechnology); CoCl2 (Sigma, St. Louis, MO, USA); FGF (Sigma) and EGF (Sigma).

**Cell line and cell culture.** The human osteosarcoma cancer cell line MG63 was purchased from the Shanghai Institute for Biological Sciences of Chinese Academy of Sciences (Shanghai, China). Cells were cultured in DMEM/F12 medium containing 10% fetal bovine serum (FBS), with 1x10^5 U/l penicillin and 100 mg/l streptomycin, in a humidified atmosphere in a 5% CO₂ incubator at 37°C.

**CCK-8 assay for the proliferation and drug resistance of MG63 cells.** To determine the effect of CoCl₂ on MG63 cell proliferation and drug resistance, MG63 cells were treated with different concentrations of CoCl₂ (0, 150 and 300 µM) for 24 h. For the proliferation assay, 1x10⁵ cells were seeded in each well of 96-well culture plates and cultured for 1 to 5 days for CCK-8 incubation. For the drug resistance assay, cells were cultured (5x10^⁴ per well) in 96-well plates for 1 day and then treated with increasing concentrations of doxorubicin and methotrexate for 24 h and then underwent CCK-8 incubation. All the cells were incubated with CCK-8 reagent for 1 h at 37°C. The staining intensity in the medium was measured by determining the absorbance at 450 nm.

**FCM analysis for Annexin V and propidium iodide (PI).** MG63 cells were cultured in 6-well plates and treated with different concentrations of CoCl₂ (0, 150 and 300 µM) for 24 h. After treatment, cells were harvested with 0.25% trypsin and collected by centrifugation at 900 × g for 5 min at room temperature. Cells were washed and re-suspended in PBS and labeled with Annexin V and PI for 20 min. Fluorescence (DNA content) was measured by FCM using standard software.

**Neurosphere/sarcosphere system assays.** MG63 cells were cultured in 6-well plates and pretreated with three concentrations of CoCl₂ (0, 150 and 300 µM) for 24 h. The cells were then plated at a density of 60,000 cells/well in 6-well ultra low attachment plates in B27 medium with the growth factors human EGF (10 ng/ml) and human FGF (10 ng/ml). Fresh aliquots of EG and FG were added every other day. After being cultured for 14 days, colonies containing >50 cells were quantitated by inverted phase contrast microscopy.

**Vertical invasion of cells.** MG63 cells were cultured in 6-well plates and pretreated with three concentrations of CoCl₂ (0, 150 and 300 µM) for 24 h. A transwell assay was used to evaluate the vertical invasion of cells. After treatment, the 6-well plates were washed twice with PBS to remove floating cells. The cells were then re-suspended in culture medium without FBS after conventional digestion. Cell suspensions (100 µl; 2.0x10^⁵/ml) were added to the upper chamber and complete culture medium was added to the lower chamber. After 24 h, the upper chamber was removed, fixed with 4% paraformaldehyde for 30 min and stained for 15 min with crystal violet. We randomly selected four fields of vision to count the number of cells which had moved to the lower membrane under a microscope, taking the average of the number of vertically migrated cells.

**Western blot analysis.** Cells were treated as described above. Protein was extracted from subconfluent cultures using lysis buffer containing 1 mM PMSF and quantified using the BCA method. Aliquots of 40 µg protein from each sample were then resolved using SDS-PAGE and subsequently transferred to PVDF membranes. Membranes were blocked in 5% milk solution and incubated with primary antibody at 4°C overnight. The membranes were then washed and incubated with horseradish peroxidase-conjugated secondary antibody (13). The immunoreactivity was detected by chemiluminescence. Statistical analyses of the western blotting data were performed on the densitometric values obtained with NIH IMAGE 1.61 software.

**Animals and transplantation assay.** To determine the in vivo tumorigenicity, we established subcutaneous and orthotopic osteosarcoma animal models. A total of 24 male BALB/C nude mice ~4-6 weeks old were purchased from and maintained at the Wuhan University Center for Animal Experiment (China). The care and use of animals followed the recommendations and guidelines of the National Institutes of Health and was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC; approval number, 2011006). The mice were randomly divided into 0 and 150 µM groups (6 per group) according to the injected cells. The experiments consisted of two parts: orthotopic and subcutaneous injections. Cells in log-phase growth were harvested, washed and re-suspended with PBS, and the BALB/C nude mice were anesthetized. For orthotopic transplantation, 5x10⁶ cells in 0.1 ml PBS were injected into the left distal femoral bone marrow cavities of each mouse. For the subcutaneous transplantation, we injected 0.1 ml PBS with 2x10⁵ cells into the back of the mice. The mice were monitored daily until one month after injection. We compared the size of the xenografted osteosarcoma tissues and the tumor formation rate of the two groups.

**Statistical analysis.** Numerical data are expressed as mean ± SD. Statistical analysis was performed by analysis of variance or Student’s t-test using the SPSS 13.0 statistical program (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant result.

**Results**

**Expression of HIF-1α increased following CoCl₂ treatment.** Western blot analysis was performed to verify if exposure of
MG63 cells to CoCl₂ induced HIF-1α expression. As shown in Fig. 1, HIF-1α was undetectable in untreated control cells, while it became detectable in the two other groups.

**Hypoxic microenvironement simulated by CoCl₂ inhibits MG63 cell proliferation but has no effect on drug resistance.** As shown in Fig. 2A, the growth curve of cells under normoxic conditions showed an ‘S’ shape: the lag phase was 1-2 days (cells grow slowly); the exponential phase of growth was 3-5 days (cells rapidly proliferated). Compared with the normoxic group, the cells of the experimental groups proliferated markedly more slowly. We further investigated the drug resistance properties, but did not find any significant differences following CoCl₂ treatment (Fig. 2B and C).

**FCM analysis of cell apoptosis induced by CoCl₂.** Following treatment with different concentrations of CoCl₂ for 24 h, apoptosis induction was demonstrated using FCM analysis. As shown in Fig. 3, in the normoxic group, cells were almost normal in appearance with rare viable apoptotic cells; while in the experimental group, the rate of apoptotic cells increased with increasing concentrations of CoCl₂. The rate of apoptosis in the normoxic, 150 and 300 µM CoCl₂ groups was 6.6, 13.0 and 18.3%, respectively. Furthermore, the proportion of apoptotic cells gradually increased in a dose-dependent manner.

**MG63 sarcospheroid formation was inhibited by CoCl₂.** All three groups of osteosarcoma cells formed spherical colonies after 10 to 14 days. However, there were marked differences between the groups. In the normoxic group, the mean number of spherical colonies formed was 210±10, whereas that of the 150 µM group was 150±5 and that of the 300 µM group was 70±7 (P<0.05). As shown in Fig. 4, the spherical colonies of the normoxic group were markedly bigger than those of the other two groups. Furthermore, the number and size of the spherical colonies gradually decreased in a dose-dependent manner.

**Inhibition of vertical invasion by CoCl₂.** In the hypoxic group, the number of cells which crossed the extracellular matrix (ECM) gel-coated filter was markedly lower than that in the normoxic group. In addition, we found that at higher concentrations of CoCl₂, fewer cells crossed the ECM gel-coated filter (Fig. 5).

**Hypoxic microenvironement inhibits tumor formation.** For the subcutaneous transplantation, we found that the 0 µM group formed xenografted osteosarcoma tissues at rate of 100%, however, the 150 µM group rarely formed the tissues. For the orthotopic transplantation, the 0 µM group formed markedly bigger tissues than the 150 µM group. At the end of the assay, the mean volume of the xenografted osteosarcoma tissues in the 0 µM group was 1.24±0.25 cm³ and that of the 150 µM group was 0.84±0.2 cm³ (P<0.05) (Fig. 6).

**Discussion**

Increasing evidence has demonstrated that intratumoral hypoxia may promote invasive growth and metastasis (14). HIF-1α is a key molecule in the hypoxic response (15) and has been found to be overexpressed in ~70% of tumors (16). However, whether HIF-1α promotes tumor cell apoptosis or has anti-apoptotic affects is controversial. Certain studies have indicated that under hypoxic conditions, the transcriptive activity of HIF-1α was increased, and this in turn enhanced the expression of down-stream genes, including VEGF, FGF and TGF-β (17,18). Thus, HIF-1α acts as a positive regulator of tumor development (19). Other studies have reported that HIF-1α upregulates VEGF and GLUT1 to make tumor cells resistant to apoptosis (20). In the present study, we demonstrated that CoCl₂ simulated a hypoxic microenvironment successfully in MG63 cells. The expression level of HIF-1α was markedly upregulated in the hypoxic microenvironment in a dose-dependent manner. This result is in accordance with those of previous studies using other tumor cell lines (21,22). By contrast, the CCK-8 assay and FCM analysis revealed that CoCl₂ inhibited the proliferation of MG63 cells.

![Figure 2](image-url)
and promoted apoptosis, and the effect was enhanced with the increased CoCl$_2$ concentration, which shows that CoCl$_2$ has the ability to inhibit osteosarcoma growth. Our data are consistent with those reported by Dai et al (23). It has also been reported that HIF-1$\alpha$ promotes apoptosis through the PI3K/Akt (24) or ERK 1/2 (25) pathways.
Cell invasive ability is a significant aspect of cancer progression which begins from the migration of tumor cells into contiguous tissues and the dissolution of the ECM. Osteosarcoma has a high tendency to metastasize, especially to the lung. Tumor hypoxia is believed to be correlated with increased metastatic potential, via the regulation of αβ3 integrin expression and promotion of tumor invasion by the tyrosine kinase receptor MET (26). We thus used a transwell invasion assay to detect whether hypoxia affects the ability of MG63 cells to metastasize. In the process of collecting cells, we removed the floating (dead) cells. We found that CoCl₂ caused a marked inhibition of invasive ability, which strongly supports the hypothesis that the hypoxic microenvironment is involved in deregulating invasion and metastasis. This was opposite from the findings of previous studies, in which hypoxic conditions elicited tumor cell phenotypes with higher migratory and invasive capacities (27,28).

Previous studies have demonstrated that tumors are composed of heterogeneous populations of cells that differ in their apparent state of self-renewal and differentiation. A subset of the cancer cell population, cancer stem cells, may play important roles in tumorigenesis, metastasis, drug resistance, and recurrence (29). The existence of cancer stem cells in tumors is now considered to be the source of tumor initiation and poor prognosis (30). Gibbs et al first demonstrated the existence of a small subpopulation of self-renewing bone sarcoma cells that were capable of forming suspended spherical clonal colonies, called “sarcospheres”, in anchorage-independent serum-starved conditions (31). Fujii et al next demonstrated the existence of these cancer stem cells in MG63 cells. The authors found that certain MG63 cells were also able to form suspended spherical colonies; furthermore, they demonstrated that these MG63 cells showed strong resistance to doxorubicin and cisplatin (32). In the present study, we found that when the concentration of CoCl₂ increased, the ability of osteosarcoma cells to form sarcospheres was diminished. Therefore, we speculate that CoCl₂ reduces the ability of the cells to self-renew and promotes the differentiation of cancer stem cells in MG63 cells, inhibiting osteosarcoma carcinogenesis.

Borenstein et al used the mammary tumor cell line LMM3 treated with CoCl₂ for 24 h to detect changes in the in vivo growth kinetics. The authors found that the tumors formed by hypoxic cells grew larger than those of controls; moreover, histological examination revealed that control tumors invaded the dermis and epidermis and induced areas of ulceration (33). The results of histological examination were in accordance with those of the present study, but it is unclear what changed the tumorigenic ability in MG63 cells treated with CoCl₂. Therefore, we further tested the tumorigenic ability of MG63 cells in vivo. In the present study, the results showed some differences compared with Borenstein et al’s. The orthotopic and subcutaneous transplantations showed that the ability to form tumors was markedly diminished in the CoCl₂-treated group. This may be due to the different sources of the tumors. However, this is consistent with the result of our neurosphere/sarcosphere system assays.

In conclusion, the present study provides evidence that the hypoxic microenvironment induced by CoCl₂ inhibits osteosarcoma development, including inhibiting proliferation, promoting apoptosis, suppressing invasion and eliminating the ability to self-renew. Although there is little information concerning the application of CoCl₂ in osteosarcoma therapy, we suggest that CoCl₂ may be used as an antitumor drug, especially in osteosarcoma. However, further investigation into the precise mechanism is required.

References

1. Ritter J and Bielack SS: Osteosarcoma. Ann Oncol 21 (Suppl 7): vii320-viii329, 2010.
2. Stellariova-Foucher E, Stillier C, Lacour B and Kaatsch P: International Classification of Childhood Cancer, third edition. Cancer 103: 1457-1467, 2005.
3. Fletcher CDM, Unni KK and Mertens F (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press, Lyon, France, pp225, 2002.
4. Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res 152: 3-13, 2009.
5. Geller DS and Gorlick R: Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 8: 705-718, 2010.
6. Tredián O, Galmairini CM, Patel K and Tannock IF: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99: 1441-1454, 2007.
7. Thömllinson RH: Hypoxia and tumors. J Clin Pathol Suppl 11: 105-113, 1977.
8. Semenza GL and Wang GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454, 1992.
9. Wang PP, Kong FP, Chen XQ and Du JZ: HIF-1 signal pathway in cellular response to hypoxia. Zhejiang Da Xue Xue Bao Yi Xue Ban 40: 559-566, 2011 (In Chinese).
10. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, et al: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-490, 1998.
11. Piret JP, Mottet D, Raes M and Michiels C: CoCl₂, a chemical inducer of hypoxia-inducible factor-1, and hypoxia reduce apoptotic cell death in hepatoma cell line HepG2. Ann NY Acad Sci 973: 443-447, 2002.
12. Goldberg MA and Schneider TJ: Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 269: 4355-4359, 1994.
13. Boccia S, Benedix H, Prager S, van de Looij J, Reinboth BS, Zimmermanns J, Schlager GW, Brait D, Siffringer M, Endesfelder S, Sizonenko S, Mallard C, Bührer C, Felderhoff-Mueser U and Gerstner B: Interaction of inflammation and hypoxia in a rat model of neonatal white matter damage. PLoS One 7: e49023, 2012.
14. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
15. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ and Harris AL: The expression and distribution of the hypoxia inducible factors HIF-1 alpha and HIF-2 alpha in normal human tissues, cancers and tumor-associated macrophages. Am J Pathol 157: 411-421, 2000.
16. Covello KL, Simon MC and Keith B: Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res 65: 2277-2286, 2005.
17. Pérez-Sayáns M, Suárez-Peñaranda JM, Pilar GD, Barros-Angueira F, Gándara-Rey JM and García-García A: Hypoxia-inducible factors in OSCC. Cancer Let 233: 1-8, 2011.
18. Andrikopoulou E, Zhang X, Sebastian R, Marti G, Liu L, Liao J, SM and Harmon JW: Current insights into the role of HIF-1 in cutaneous wound healing. Curr Mol Med 11: 218-235, 2011.
19. Chouaib S, Messia Y, Couve S, Escudier B, Hamas M and Noman MZ: Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol 3: 21, 2012.
20. Dai S, Huang ML, Hsu CY and Chao KS: Inhibition of hypoxia inducible factor Ialpha causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in glioblastoma cells. Int J Radiat Oncol Biol Phys 55: 1027-1036, 2003.
21. Xing D, Sun X, Li J, Cui M, Tan-Allen K and Bonanno JA: Hypoxia preconditioning protects corneal stromal cells against induced apoptosis. Exp Eye Res 82: 780-787, 2006.

22. Akakura N, Kobayashi M, Horizuchi I, Suzuki A, Wang J, Chen J, Niizeki H, Kawamura Ki, Hosokawa M and Asaka M: Constitutive expression of hypoxia-inducible factor-lalpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61: 6548-6554, 2001.

23. Dai ZJ, Gao J, Ma XB, Yan K, Liu XX, Kang HF, Ji ZZ, Guan HT and Wang XJ: Up-regulation of hypoxia inducible factor-1α by cobalt chloride correlates with proliferation and apoptosis in PC-2 cells. J Exp Clin Cancer Res 31: 28, 2012.

24. Ardyanto TD OM, Tokuyasu N, Nagahama Y and Ito H: CoCl₂-induced HIF-1alpha expression correlates with proliferation and apoptosis in MKN-1 cells: a possible role for the PI3K/Akt pathway. Int J Oncol 29: 549-555, 2006.

25. Yang SJ, Pyen J, Lee I, Lee H, Kim Y and Kim T: Cobalt chloride-induced apoptosis and extracellular signal-regulated protein kinase 1/2 activation in rat C6 glioma cells. J Biochem Mol Biol 37: 480-486, 2004.

26. Brahimi-Horn C and Pouyssegur J: The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer 93: E73-80, 2006.

27. Cowden Dahl KD, Robertson SE, Weaver VM and Simon MC: Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression. Mol Biol Cell 16: 1901-1912, 2005.

28. Kalpana S, Dhananjay S, Anju B, Lilly G and Sai Ram M: Cobalt chloride attenuates hypobaric hypoxia induced vascular leakage in rat brain: molecular mechanisms of action of cobalt chloride. Toxicol Appl Pharmacol 231: 354-363, 2008.

29. Dalerba P, Cho RW and Clarke MF: Cancer stem cells: models and concepts. Annu Rev Med 58: 267-284, 2007.

30. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer stem cells - perspectives on current status and future directions: AACS Workshop on cancer stem cells. Cancer Res 66: 9339-9344, 2006.

31. Gibbs CP, Kukkov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN and Steindler DA: Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7: 967-976, 2005.

32. Fuji H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K and Takakura Y: Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int J Oncol 34: 1381-1386, 2009.

33. Borenstein X, Fiszman GL, Blidner A, Vanzulli SI and Jasnis MA: Functional changes in murine mammary cancer cells elicited by CoCl₂-induced hypoxia. Nitric Oxide 23: 234-241, 2010.